Resumen
This commentary aims to highlight some of the major issues (with possible solutions) that the Latin American region is currently dealing with in managing post-COVID-19 pulmonary fibrosis. Overall, there is little evidence for successful long-term COVID-19 follow-up treatment. The lack of knowledge regarding proper treatment is exacerbated in Latin America by a general lack of resources devoted to healthcare, and a lack of availability and access to multidisciplinary teams. The discussion suggests that better infrastructure (primarily multicenter cohorts of COVID-19 survivors) and well-designed studies are required to develop scientific knowledge to improve treatment for the increasing prevalence of pulmonary fibrosis in Latin America.
| Idioma original | Inglés |
|---|---|
| Número de artículo | 1393 |
| Publicación | Journal of Personalized Medicine |
| Volumen | 12 |
| N.º | 9 |
| DOI |
|
| Estado | Publicada - sep. 2022 |